Biomarker-Driven Lung Cancer

Treatment with the tyrosine kinase inhibitor entrectinib may lead to continued clinical benefit as treatment of patients with ROS1-positive non–small cell lung cancer, including those with central nervous system metastases, according to an updated from an integrated analysis of 3 clinical trials.

Telisotuzumab vedotin monotherapy demonstrated a promising objective response rate and has a tolerable safety profile in patients with previously treated c-Met–positive advanced non–small cell lung cancer, according to findings from a phase 2 trial presented in a poster at the American Association for Cancer Research Annual Meeting 2021.

Vivek Subbiah, MD, explored the treatment options for RET-fusion positive non–small cell lung cancer during a virtual Targeted Oncology Case-Based Roundtable event.

The FDA has granted a fast-track designation to the tyrosine kinase inhibitor, poziotinib for the treatment of previously treated patients with non-small cell lung cancer whose tumors harbor a HER2 exon 20 mutation.

The FDA accepted a new drug application for sotorasib and granted it a priority review for the treatment of patients with KRAS G12C–mutant locally advanced or metastatic non–small cell lung cancer following at least 1 prior systemic treatment.

Trastuzumab deruxtecan induced a high objective response rate and durable responses among patients with HER2-mutant non–small cell lung cancer in a cohort of the phase 2 DESTINY Lung-01 trial, according to interim findings presented during the 2020 World Conference on Lung Cancer Singapore.

During a Targeted Oncology Case-Based Peer Perspectives event, Todd Bauer, MD, medical oncologist, Tennessee Oncology, discussed the results from clinical trials that include patients with RET-altered lung cancer to determine a treatment strategy for a 59-year-old patient.

The FDA has granted an accelerated approval to tepotinib for the treatment of adult patients with metastatic non–small cell lung cancer who harbor a MET exon 14 skipping alteration.

Larotrectinib was observed to be highly active and have a favorable safety profile in patients with advanced lung cancer whose tumors harbor an NTRK gene fusion, including those with central nervous system metastases.

Treatment with the next-generation ROS1 and TRK tyrosine kinase inhibitor repotrectinib is sustaining good objective responses and is tolerable in patients with ROS1 fusion–positive non–small cell lung cancer, according to updated preliminary results from the phase 2 expansion 1 cohort of the ongoing phase 1/2 TRIDENT-1 clinical trial.

In the phase 3 VISION study, treatment with the MET inhibitor, tepotinib showed durable clinical activity as treatment of patients with MET exon 14 skipping non‒small cell lung cancer.

Lyudmila A. Bazhenova, MD, explains the impact of having larotrectinib results in a lung cancer cohort, as seen in a presentation of data from 14 patients, given during the 2020 World Conference on Lung Cancer Singapore.

Antitumor activity was demonstrated with trastuzumab deruxtecan treatment in patients with HER2-overexpressing non–small cell lung cancer, regardless of HER2 expression levels, according to interim findings from a cohort of the phase 2 DESTINY Lung-01 trial.

Sotorasib demonstrated significant benefit in patients with KRAS G12C–mutated advanced non–small cell lung cancer, according to results from the phase 2 portion of the CodeBreaK 100 trial to be presented at the International Association for the Study of Lung Cancer 2020 World Conference on Lung Cancer.

Larger, retrospectives studies are needed after NRG1 fusions were detected in patients with non-small cell lung cancer.

Tony S. K. Mok, BMSc, MD, FRCPC, discusses the ADAURA trial of osimertinib in patients with non–small cell lung cancer.

In an interview with Targeted Oncology, Vivek Subbiah, MD, discussed the role of selpercatinib as treatment of patients with RET fusion-positive NSCLC, which is supported by findings from the LIBRETTO-001 study.

Patients with ROS1-positive non–small cell lung cancer who have resistance to the ROS1 and ALK inhibitor crizotinib had intracranial and systemic responses to brigatinib, according to findings from a small cohort of patients.

FDA approvals of novel agents for molecularly defined subtypes of non–small cell lung cancer are poised to change both patient outcomes as well as pretreatment testing requirements for those harboring these tumors.

A New Drug Application was submitted to the FDA seeking approval of the investigational KRAS G12C inhibitor sotorasib as treatment of patients with KRAS G12C-mutated locally advanced or metastatic non–small cell lung cancer, as determined by an FDA-approved test, following at least 1 prior systemic therapy.

Alexander Spira, MD, PhD, discusses how he chooses treatment for patients with lung cancer.

The FDA granted a Breakthrough Therapy designation to sotorasib for the treatment of patients with locally advanced or metastatic non–small cell lung cancer who harbored a KRAS G12C mutation following at least 1 prior line of systemic therapy.

Treatment with lorlatinib induced a 72% reduction in the risk of progression or death compared with crizotinib in patients with previously untreated ALK-positive advanced non–small cell lung cancer.

In an interview with Targeted Oncology, Alexander Spira, MD, PhD, discussed the role of identifying biomarkers in patients with lung cancer based on the vast amount of data and significant number of approved therapies available for biomarker-driven disease.

Benjamin Solomon, MBBS, PhD, discusses the intracranial responses observed in the CROWN trial of lorlatinib versus crizotinib in patients with ALK-positive non–small cell lung cancer.